Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (11)

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology

2022

  1. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

    European Journal of Cancer, Vol. 175, pp. 110-119

2020

  1. Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer

    European Urology

2019

  1. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

    Critical Reviews in Oncology/Hematology, Vol. 138, pp. 190-206

2017

  1. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 1, pp. 40-47

2016

  1. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations

    Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141

  2. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02

    Annals of Oncology, Vol. 27, pp. vi277

2015

  1. New advances in genitourinary cancer: evidence gathered in 2014

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 443-464

2014

  1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 6, pp. 1095-1107

  2. SEOM clinical guidelines for the treatment of renal cell carcinoma

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1043-1050